Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;27(11):1013-1023.
doi: 10.1111/tmi.13824. Epub 2022 Oct 31.

Level of adherence to anti-tubercular treatment among drug-sensitive tuberculosis patients on a newly introduced daily dose regimen in South India: A cross-sectional study

Rajavardhana Thamineni  1   2 , Ramalingam Peraman  3 , Jayakumar Chenniah  4 , Geethavani Meka  2 , Ashok Kumar Munagala  5 , Vijayakumar Thangavel Mahalingam  6 , Rajanandh Muhasaparur Ganesan  1
Affiliations
Free article

Level of adherence to anti-tubercular treatment among drug-sensitive tuberculosis patients on a newly introduced daily dose regimen in South India: A cross-sectional study

Rajavardhana Thamineni et al. Trop Med Int Health. 2022 Nov.
Free article

Abstract

Introduction: Tuberculosis (TB) patients on the National Tuberculosis Elimination Program (NTEP) treatment protocol receive daily doses without health professional-supervised drug intake as during the previous directly observed treatment short-course (DOTS) regimen. We aimed to measure the level of adherence to anti-tubercular treatment (ATT) and the reasons for non-adherence among drug-sensitive TB patients on a daily-dose regimen in South India.

Methods: A cross-sectional study was conducted among TB patients who received ATT as part of the standard treatment protocol in NTEP. Patients were interviewed to capture their understanding of TB, adherence, and the reason for non-adherence to ATT using validated instruments. Urine drug metabolite testing was performed using the high-performance liquid chromatography (HPLC) technique to confirm adherence.

Results: A total of 488 patients were recruited for the study. 64.8% of patients had 'good knowledge' about TB and ATT. According to the subjective report, 63.7% of patients were adherent, but urine drug metabolite testing revealed 53.4% adherence. A statistically significant difference (p < 0.05) exists between subjective and objective adherence measures. Patient-reported reasons for non-adherence were side effects of ATT (18.6%), loss of daily wages (15.0%), and forgetfulness (10.0%), among others.

Conclusions: Nearly half of the patients were non-adherent to the daily dosing regimen. Adherence as reported by the patients is unreliable, and urine testing could be used in routine care to assess adherence.

Clinical trial registration and number: CTRI/2020/04/024941.

Keywords: 99DOTS; antimicrobial agents; ethambutol; isoniazid; pyrazinamide; rifampicin.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Clinical standards for the management of adverse effects during treatment for TB.
    Singh KP, Carvalho ACC, Centis R, D Ambrosio L, Migliori GB, Mpagama SG, Nguyen BC, Aarnoutse RE, Aleksa A, van Altena R, Bhavani PK, Bolhuis MS, Borisov S, van T Boveneind-Vrubleuskaya N, Bruchfeld J, Caminero JA, Carvalho I, Cho JG, Davies Forsman L, Dedicoat M, Dheda K, Dooley K, Furin J, García-García JM, Garcia-Prats A, Hesseling AC, Heysell SK, Hu Y, Kim HY, Manga S, Marais BJ, Margineanu I, Märtson AG, Munoz Torrico M, Nataprawira HM, Nunes E, Ong CWM, Otto-Knapp R, Palmero DJ, Peloquin CA, Rendon A, Rossato Silva D, Ruslami R, Saktiawati AMI, Santoso P, Schaaf HS, Seaworth B, Simonsson USH, Singla R, Skrahina A, Solovic I, Srivastava S, Stocker SL, Sturkenboom MGG, Svensson EM, Tadolini M, Thomas TA, Tiberi S, Trubiano J, Udwadia ZF, Verhage AR, Vu DH, Akkerman OW, Alffenaar JWC, Denholm JT. Singh KP, et al. Int J Tuberc Lung Dis. 2023 Jul 1;27(7):506-519. doi: 10.5588/ijtld.23.0078. Int J Tuberc Lung Dis. 2023. PMID: 37353868 Free PMC article.
  • Barriers to engagement in the care cascade for tuberculosis disease in India: A systematic review of quantitative studies.
    Jhaveri TA, Jhaveri D, Galivanche A, Lubeck-Schricker M, Voehler D, Chung M, Thekkur P, Chadha V, Nathavitharana R, Kumar AMV, Shewade HD, Powers K, Mayer KH, Haberer JE, Bain P, Pai M, Satyanarayana S, Subbaraman R. Jhaveri TA, et al. PLoS Med. 2024 May 28;21(5):e1004409. doi: 10.1371/journal.pmed.1004409. eCollection 2024 May. PLoS Med. 2024. PMID: 38805509 Free PMC article.
  • Treatment and Toxicity Considerations in Tuberculosis: A Narrative Review.
    Jones NT, Abadie R, Keller CL, Jones K, Ledet Iii LF, Fox JE, Klapper VG, Potharaju P, Siddaiah H, Kaye AM, Shekoohi S, Kaye AD, Varrassi G. Jones NT, et al. Cureus. 2024 Jun 19;16(6):e62698. doi: 10.7759/cureus.62698. eCollection 2024 Jun. Cureus. 2024. PMID: 39036175 Free PMC article. Review.
  • Adherence to treatment on a daily-dose regimen for TB.
    Rajavardhana T, Koushik MR, Jayakumar C, Ramalingam P, Geethavani M, Kumar MA, Rajanandh MG. Rajavardhana T, et al. Int J Tuberc Lung Dis. 2023 Oct 1;27(10):778-780. doi: 10.5588/ijtld.23.0054. Int J Tuberc Lung Dis. 2023. PMID: 37749830 Free PMC article. No abstract available.
  • Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial.
    Perumal Kannabiran B, Palaniappan NA, Manoharan T, Paramasivam PK, Saini JK, Ansari MS, Jayabal L, Aggarwal AN, Garg R, Subramanyam B, Thakur D, Pantula S, P M R, Gs V, Natarajan S, Ammayappan RK, Manpreet B, Ganesan M, Angamuthu D, Chinnaiyan P, Singh M, Chandrasekaran P, Swaminathan S. Perumal Kannabiran B, et al. Open Forum Infect Dis. 2024 Feb 2;11(3):ofae034. doi: 10.1093/ofid/ofae034. eCollection 2024 Mar. Open Forum Infect Dis. 2024. PMID: 38444824 Free PMC article. Clinical Trial.

References

REFERENCES

    1. National TB Elimination Programme. Guidelines for programmatic management of TB preventive treatment in India 2021 2021. Available from: https://tbcindia.gov.in/WriteReadData/l892s/Guidelines%20for%20Programma.... Accessed 12 Dec 2021.
    1. World Health Organization. Global tuberculosis report 2019. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/globa.... Accessed 26 Sep 2021.
    1. World Health Organization. Global tuberculosis report 2020. Available from: https://www.who.int/publications/i/item/9789240013131. Accessed 26 Sep 2021.
    1. World Health Organization. Global Tuberculosis Report 2018-World | ReliefWeb. Available from: https://reliefweb.int/report/world/global-tuberculosis-report-2018. Accessed 26 Sep 2021.
    1. World Health Organization. Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis. Available from: https://www.who.int/publications/i/item/9789241514101. Accessed 26 Sep 2021.

Publication types

LinkOut - more resources